This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Review of Our Experience

Shigeto Morimoto, MD, PhD; Kunihiko Yoshikawa, MD, PhD

Arch Dermatol. 1989;125(2):231-234.

Abstract
• Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D₃) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D₃ in both oral and topical ways in an opendesign study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D₃ are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease.

(Arch Dermatol 1989;125:231-234)

Author Affiliations
From the Departments of Geriatric Medicine (Dr Morimoto) and Dermatology (Dr Yoshikawa), Osaka University Medical School, Osaka, Japan.

Footnotes
Accepted for publication Sept 14, 1988.

Reprint requests to Department of Geriatric Medicine, Osaka University Medical School, Fukushima-Ku, Osaka 553, Japan (Dr Morimoto).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Will 1,25-Dihydroxyvitamin D3, MC 903, and Their Analogues Herald a New Pharmacologic Era for the Treatment of Psoriasis?
Holick
Arch Dermatol 1989;125:1692-1697.
ABSTRACT